ATF4/TXNIP/REDD1/mTOR signaling mediates the antitumor activities of liver X receptor in pancreatic cancers.
Zhikang ChenXiaobo LaiHui DingAijun ZhangYufei SunJianhua LingPaul J ChiaoZihua ChenXuefeng XiaPublished in: Cancer innovation (2022)
This study provides the pre-clinical evidence that LXR agonist is a promising therapy for pancreatic cancer.
Keyphrases